- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Updated DWI Software for Portable MRI Neuroimaging Device
The new software for the Swoop® Portable MR Imaging system reportedly enhances the signal-to-noise ratio for diffusion-weighted imaging (DWI) sequences by 42 percent in comparison to the previous software.
The Food and Drug Administration (FDA) has granted 510(k) clearance to new software for the Swoop® Portable MR Imaging device that may significantly enhance the quality of diffusion-weighted magnetic resonance imaging (MRI) for neurocritical patients.
The new software offers a 42 percent increase in the signal-to-noise ratio for diffusion-weighted imaging (DWI) sequences, according to Hyperfine, the manufacturer of the device. The company noted other benefits of the software include additional compensation for subtle patient movements and more uniform imaging for DWI sequences.
Emphasizing the key role DWI imaging plays in facilitating prompt diagnosis of an array of neurological conditions as well as the monitoring of stroke progression, Hyperfine said the updated software will provide a significant advance in care for high-risk populations.
“With this latest software, Swoop system images provide increasingly valuable diagnostic images that can aid clinicians in caring for neurocritical patients,” noted Edward Knopp, M.D., the senior medical director with Hyperfine.
Hyperfine received an FDA 510(k) clearance earlier this month for the device’s updated brain imaging software. The company said the updated DWI software will be available in March 2023.
(Editor’s note: For related content, see “Emerging Deep Learning System May Enhance MRI Assessment of Intracranial Tumors” and “FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting.”)
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
